Sublingual allergen immunotherapy: Mode of action and its relationship with the safety profile

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 67, Issue 3, 2012, Pages 302-311

  Calderon M A ^a   Simons, F E R ^b   Malling, H J ^c   Lockey, R F ^d   Moingeon, P ^e   Demoly, P ^f  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANITOBA   (Canada)

^c Mental Health Services CPH   (Denmark)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e Stallergenes SA   (France)

^f HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

allergen immunotherapy; mucosal; safety; subcutaneous; sublingual

Indexed keywords

ADRENALIN; ALLERGEN; AMINOPHYLLINE; ANTIHISTAMINIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; LORATADINE; METHYLPREDNISOLONE; PREDNISONE; SALBUTAMOL;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ALLERGIC REACTION; ALLERGIC RHINITIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIGEN PRESENTING CELL; ASTHMA; CD4+ T LYMPHOCYTE; CHEST TIGHTNESS; CLINICAL FEATURE; COLLAPSE; CONJUNCTIVITIS; DIZZINESS; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; EYE EDEMA; FAINTNESS; FLUSHING; FOOT EDEMA; HAND EDEMA; HUMAN; HYPOTENSION; IMMUNE RESPONSE; INTERMETHOD COMPARISON; MOUTH DISEASE; MOUTH EDEMA; NONHUMAN; PALATE DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROVOCATION TEST; PRURITUS; REVIEW; RHINITIS; RHINOCONJUNCTIVITIS; RISK FACTOR; SHIVERING; SIDE EFFECT; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TH1 CELL; THORAX PAIN; URTICARIA; VOMITING; WHEEZING;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; AGED; ALLERGENS; ANAPHYLAXIS; ANIMALS; CHILD; CHILD, PRESCHOOL; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MOUTH MUCOSA; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, SEASONAL; YOUNG ADULT;

EID: 84857191354     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2011.02761.x     Document Type: Review

References (42)

1. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, et al., Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009; 64 (Suppl 91): 1-59.
2. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al., Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl 86): 8-160.
3. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al., Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126: 466-476.
4. Radulovic S, Wilson D, Calderon M, Durham S,. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011; 66: 740-752.
5. Kaul S, May S, Luttkopf D, Vieths S,. Regulatory environment for allergen-specific immunotherapy. Allergy 2011; 66: 753-764.
6. Cox LS, Larenas-Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS,. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006; 117: 1021-1035.
7. Bernstein DI, Wanner M, Borish L, Liss GM,. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004; 113: 1129-1136.
8. Bernstein DI, Epstein T, Murphy-Berendts K, Liss GM,. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study. Ann Allergy Asthma Immunol 2010; 104: 530-535.
9. Bernardis P, Agnoletto M, Puccinelli P, Parmiani S, Pozzan M,. Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients. J Investig Allergol Clin Immunol 1996; 6: 55-62.
10. Quirino T, Iemoli E, Siciliani E, Parmiani S, Milazzo F,. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996; 26: 1253-1261.
11. Mungan D, Misirligil Z, Gürbüz L,. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma-a placebo controlled study. Ann Allergy Asthma Immunol 1999; 82: 485-490.
12. Khinchi MS, Poulsen LK, Carat F, André C, Hansen AB, Malling HJ,. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004; 59: 45-53.
13. Herrscher RF,. Evaluation of three allergen specific immunotherapy methods: standard injection, rush injection and sublingual. Ann Allergy Asthma Immunol 2006; 96: 148.
14. Mauro M, Russello M, Incorvaia C, Gazzola GB, Di Cara G, Frati F,. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study. Eur Ann Allergy Clin Immunol 2007; 39: 119-122.
15. Incorvaia C, Mauro M, Ridolo E, Puccinelli P, Liuzzo M, Scurati S, et al., Patient's compliance with allergen immunotherapy. Patient Prefer Adherence 2008; 2: 247-251.
16. Sieber J, De Geest S, Shah-Hosseini K, Mösges R,. Medication persistence with long-term, specific grass pollen immunotherapy measured by prescription renewal rates. Curr Med Res Opin 2011; 27: 855-861.
17. Novak N, Bieber T, Allam J-P,. Immunological mechanisms of sublingual allergen-specific immunotherapy. Allergy 2011; 66: 733-739.
18. Cox L,. Sublingual immunotherapy and allergic rhinitis. Curr Allergy Asthma Rep 2008; 8: 102-110.
19. Mascarell L, Lombardi V, Louise A, Saint-Lu N, Chabre H, Moussu H, et al., Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells. J Allergy Clin Immunol 2008; 122: 603-609.
20. Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E, et al., Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy 2001; 31: 54-60.
21. Allam JP, Stojanovski G, Friedrichs N, Peng W, Bieber T, Wenzel J, et al., Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy 2008; 63: 720-727.
22. Mascarell L, Lombardi V, Zimmer A, Louise A, Tourdot S, Van Overtvelt L, et al., Mapping of the lingual immune system reveals the presence of both regulatory and effect CD4+ T cells. Clin Exp Allergy 2009; 39: 1910-1919.
23. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling H-J, et al., Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for Respiratory Allergy: a Statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62: 317-324.
24. Antico A, Pagani M, Crema A,. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006; 61: 1236-1237.
25. Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA,. Anaphylaxis to sublingual immunotherapy. Allergy 2006; 61: 1235.
26. Eifan AO, Keles S, Bahceciler NN, Barlan IB,. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007; 62: 567-568.
27. André C, Fadel R,. Anaphylaxis caused by allergen sublingual immunotherapy? Allergy 2007; 62: 1220-1221.
28. Blazowski L,. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008; 63: 374.
29. Rodríguez-Pérez N, Ambriz-Moreno Mde J, Canonica GW, Penagos M,. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol 2008; 101: 304-310.
30. de Groot H, Bijl A,. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009; 64: 963-964.
31. Buyukozturk S, Gelincik A, Ozşeker F, Colakoǧlu B, Dal M,. Latex sublingual immunotherapy: can its safety be predicted? Ann Allergy Asthma Immunol 2010; 104: 339-342.
32. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al., Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117: 391-397.
33. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G,. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010; 125: 569-574.
34. Simons FER, Ardusso LRF, Bilo MB, El-Gamal YM, Ledford DK, Ring J, et al., World Allergy Organization guidelines for the assessment and management of anaphylaxis. J Allergy Clin Immunol 2011; 127: 587-593.
35. Triggiani M, Patella V, Staiano RI, Granata F, Marone G,. Allergy and the cardiovascular system. Clin Exp Immunol 2008; 153 (Suppl 1): 7-11.
36. Lieberman P, Nicklas RA, Oppenheimer J, Kemp SF, Lang DM, Bernstein DI, et al., The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126: 477-480. e1-42.
37. Lopez DGL,. Systemic reactions secondary to allergen-specific immunotherapy in a population of Monterrey, Mexico. J Allergy Clin Immunol 2003; 111: S72.
38. Rueff F, Przybilla B, Bilo MB, Muller U, Scheipl F, Aberer W, et al., Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: Importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124: 1047-1054.
39. Roy SR, Sigmon JR, Olivier J, Moffitt JE, Brown DA, Marshall GD,. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 2007; 99: 82-86.
40. Malling HJ, Montagut A, Melac M, Patriarca G, Panzner P, Seberova E, et al., Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy 2009; 39: 387-393.
41. Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, et al., Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125: 131-138. e1-7.
42. Valent P, Horny HP, Triggiani M, Arock M,. Clinical and laboratory parameters of mast cell activation as basis for the formulation of diagnostic criteria. Int Arch Allergy Immunol 2011; 156: 119-127.